Table 2.
Case reports about LIT in patients with renal impairment
| Study | Age | Gender | Infection | Linezolid initial dose | Dose reduction | Renal function | Thrombocytopenia | Outcome |
|---|---|---|---|---|---|---|---|---|
| Cossu et al., 2014 [5] | 72 | Woman | MRSA pulmonary infection | 600 mg b.i.d. | Discontinuation | CRRT | 32*10^9/L | Thrombocytes reached normal levels 7 days after discontinuation |
| Tsuji et al., 2015 [9] | 78 | Man | MRSA mediastinitis | 600 mg o.d. | 300 mg o.d. | 8.6 mL/min/1.73 m2 | 65*10^9/L | Thrombocyte count recovered and infection was successfully treated with linezolid |
| Taguchi et al., 2013 [11] | 87 | Woman | MRSA | 1200 mg/day | 600 mg o.d. | 30 mL/min | 54*10^9/L | Decreased dose was well tolerated, no thrombocytopenia occurred |
| Xiao et al., 2018 [23] | 50 | Woman | MRSA endocarditis | 600 mg b.i.d. | None | 23 mL/min/1.73 m2 | 12*10^9/L | Died from multiple organ failure |
b.i.d. bis in die = twice a day, CRRT continuous renal replacement therapy, o.d. omne in die = once a day